| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA4441327
Max Phase: Preclinical
Molecular Formula: C46H52N12O6
Molecular Weight: 869.00
Molecule Type: Unknown
Associated Items:
Representations
Canonical SMILES: CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCN(Cc5cn(CCCCCCc6cccc7c6C(=O)N(C6CCC(=O)NC6=O)C7=O)nn5)CC4)cn3)nc2n(C2CCCC2)c1=O
Standard InChI: InChI=1S/C46H52N12O6/c1-28-35-25-48-46(51-41(35)57(32-12-6-7-13-32)44(63)39(28)29(2)59)49-37-17-15-33(24-47-37)55-22-20-54(21-23-55)26-31-27-56(53-52-31)19-8-4-3-5-10-30-11-9-14-34-40(30)45(64)58(43(34)62)36-16-18-38(60)50-42(36)61/h9,11,14-15,17,24-25,27,32,36H,3-8,10,12-13,16,18-23,26H2,1-2H3,(H,50,60,61)(H,47,48,49,51)
Standard InChI Key: SPVZNAIMPMIRCT-UHFFFAOYSA-N
Associated Targets(Human)
Protein cereblon/Cyclin-dependent kinase 6 113 Activities
Protein cereblon/Cyclin-dependent kinase 4 68 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 869.00 | Molecular Weight (Monoisotopic): 868.4133 | AlogP: 4.67 | #Rotatable Bonds: 15 |
| Polar Surface Area: 210.51 | Molecular Species: NEUTRAL | HBA: 16 | HBD: 2 |
| #RO5 Violations: 2 | HBA (Lipinski): 18 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 2 |
| CX Acidic pKa: 11.15 | CX Basic pKa: 5.66 | CX LogP: 4.84 | CX LogD: 4.83 |
| Aromatic Rings: 5 | Heavy Atoms: 64 | QED Weighted: 0.08 | Np Likeness Score: -1.03 |
References
| 1. Su S, Yang Z, Gao H, Yang H, Zhu S, An Z, Wang J, Li Q, Chandarlapaty S, Deng H, Wu W, Rao Y.. (2019) Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders., 62 (16): [PMID:31330105] [10.1021/acs.jmedchem.9b00871] |
Source
Source(1):